{"id":496760,"date":"2020-07-17T13:52:01","date_gmt":"2020-07-17T13:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496760"},"modified":"2020-07-17T13:52:01","modified_gmt":"2020-07-17T13:52:01","slug":"peripheral-tcell-lymphomas-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/peripheral-tcell-lymphomas-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020_496760.html","title":{"rendered":"Peripheral T-Cell Lymphomas Global API Manufacturers, Marketed and Phase III Drugs Landscape &#8211; 2020"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Peripheral T-Cell Lymphomas Global API Manufacturers, Marketed and Phase III Drugs Landscape - 2020\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Peripheral T-Cell Lymphomas Global API Manufacturers, Marketed and Phase III Drugs Landscape - 2020\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Peripheral T-Cell Lymphomas (PTCL) &#8211; Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 report by DelveInsight offers comprehensive insights on marketed and Phase III products for Peripheral T-Cell Lymphomas (PTCL). The marketed products information covers their product details, patents (US &#038; EU), historical and forecasted sales till 2023. It further provides the marketed products API manufacturer details for United States, Europe, China, and India. <\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphomas-ptcl-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\" target=\"_blank\">Report Methodology of&nbsp;Peripheral T-Cell Lymphomas (PTCL)<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\"><span>Detailed description of the indication including causes, symptoms, pathophysiology, diagnosis and treatment<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Comparative analysis of the marketed and emerging products&nbsp;<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Detailed profiles for the marketed therapies available including mechanism of action, dosage and administration regulatory milestones, other development activities&nbsp;<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Global sales of the marketed therapies from 2012-2023 is covered in the report<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Global API Manufacturers for marketed therapies are provided across United States, Europe, China and India<\/span><\/li>\n<li class=\"ql-align-justify\"><span>List of emerging therapies with product name, company, stage of development, indication, route of administration and molecule type is also provided&nbsp;&nbsp;<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">Scope of the Report<\/span><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\"><span>The Peripheral T-Cell Lymphomas (PTCL) report provides a comprehensive understanding of Peripheral T-Cell Lymphomas (PTCL) marketed and emerging (Phase III) products<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Access to API manufacturers details for Peripheral T-Cell Lymphomas (PTCL) marketed drugs to devise API procurement strategy for generic development<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Plan developmental timelines around marketed drug patents for the major markets- US and EU<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Understand current and future growth of marketed Peripheral T-Cell Lymphomas (PTCL) therapeutics through their historical and forecasted sales<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Identify and analyze future sales trends of emerging Phase III Peripheral T-Cell Lymphomas (PTCL) therapeutics through their forecasted sales<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Identify the products attributes and use it for target finding, drug repurposing, and precision medicine<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Identify and plan ahead for prospective emerging players and their products for Peripheral T-Cell Lymphomas (PTCL)<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/peripheral-t-cell-lymphomas-ptcl-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\" target=\"_blank\">Request for sample pages<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents<\/strong><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>1.&nbsp;<\/span><span>Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2.&nbsp;<\/span><span>Peripheral T-Cell Lymphomas (PTCL)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.1.&nbsp;<\/span><span>Peripheral T-Cell Lymphomas (PTCL)<\/span><span>&nbsp;Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.2.&nbsp;<\/span><span>Peripheral T-Cell Lymphomas (PTCL)<\/span><span>&nbsp;Causes&nbsp;&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.3.&nbsp;<\/span><span>Peripheral T-Cell Lymphomas (PTCL)&nbsp;<\/span><span>Types&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.4.&nbsp;<\/span><span>Peripheral T-Cell Lymphomas (PTCL)<\/span><span>&nbsp;Risk Factors \/ Complications<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.5.&nbsp;<\/span><span>Peripheral T-Cell Lymphomas (PTCL)<\/span><span>&nbsp;Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6.&nbsp;<\/span><span>Peripheral T-Cell Lymphomas (PTCL)<\/span><span>&nbsp;Diagnosis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.7.&nbsp;<\/span><span>Peripheral T-Cell Lymphomas (PTCL)<\/span><span>&nbsp;Treatment<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3.<\/span><span>&nbsp;Comparative Analysis of Marketed and Emerging Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1. Marketed Products<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.&nbsp;<\/span><span>Drug A<\/span><span>: Company&nbsp;<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.2. Regulatory Milestones<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.3. Product Development Activities<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.3.1. General Description Table<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.4. Global Sales<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.5. Global API Manufacturers for Drug A<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.5.1. United States<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.5.2. Europe<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.5.3. China&nbsp;<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.1.5.4. India<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.&nbsp;<\/span><span>Drug B<\/span><span>: Company<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.2. Regulatory Milestones<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.3. Product Development Activities<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.3.1. General Description Table<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.4. Global Sales<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.5. Global API Manufacturers for Drug B<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.5.1. United States<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.5.2. Europe<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.5.3. China&nbsp;<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.2.5.4. India<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>Complete details in the report<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.3. Emerging Therapies &#8211; Late Phase&nbsp;<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>3.1.3.1. List of Phase III drugs for&nbsp;<\/span><span>Peripheral T-Cell Lymphomas (PTCL)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4.&nbsp;<\/span><span>Appendix<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5.&nbsp;PTCL&nbsp;<\/span><span>Report Methodology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1. Secondary Research<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.2. Expert Panel Validation<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=peripheral-tcell-lymphomas-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=peripheral-tcell-lymphomas-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Peripheral T-Cell Lymphomas (PTCL) &#8211; Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 report by DelveInsight offers comprehensive insights on marketed and Phase III products for Peripheral T-Cell Lymphomas (PTCL). The marketed products information covers their product &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/peripheral-tcell-lymphomas-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020_496760.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-496760","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=496760"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496760\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=496760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=496760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=496760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}